Tick-borne encephalitis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ilan Dock, B.S.

Tick-borne encephalitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Tick-borne encephalitis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
MRI
CT
Other Diagnostic Studies
Treatment
Medical Therapy
Future or Investigational New Therapies
Prevention
Case Studies
Case #1
Tick-borne encephalitis classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tick-borne encephalitis classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Tick-borne encephalitis classification
CDC on Tick-borne encephalitis classification
Tick-borne encephalitis classification in the news
Blogs on Tick-borne encephalitis classification
Directions to Hospitals Treating Tick-borne encephalitis
Risk calculators and risk factors for Tick-borne encephalitis classification

Classification

• TBE virus has three subtypes:

1. Siberian subtype (Tick vector: unknown)
2. Far Eastern subtype (Tick vector: Ixodes persulcatus)
3. European subtype (Tick vector: Ixodes ricinus)

• Subtypes may be useful in predicting the severity of infection.
• The following expresses the three major and most common subtypes responsible for human infection, as well as the associated symptoms.

Subtype	Clinical manifestations
Siberian	May persist as a chronic disease. 5% of cases present in focal encephalitic forms 47% present in meningeal forms 40% present in febrile forms 21% present in a biphasic form. Fatality is apporxiamtely 2%, with continuous complications and a potentially chronic condition.
Far Eastern	31-64% of cases present in focal encephalitic forms. 26% present in meningeal forms 14-16% present in febrile forms 3-8% present in biphasic forms 25% of cases recover fully Fatality is approximately 35% and chronic disease develops is an estimated 0.5% of patients.
European	72-87% experience a biphasic illness. The first phase includes an onset of non-specific flu like symptoms. Following phase one is a remission period of approximately 8 days, during which phase most patients will appear asymptomatic. Further neurological manifestations will appear in phase two. 20-30% of patients will progress in to phase two. Clinical characteristic features of the second stage include meningitis, meningoencephalitis, meningoencephalomyelitis, and meningoencephaloradiculitis. Fatality occurs in less than 2% of cases.